See more : Fresenius Medical Care AG & Co. KGaA (FME.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Intercept Pharmaceuticals, Inc. (ICPT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Intercept Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Enlight Renewable Energy Ltd (ENLT) Income Statement Analysis – Financial Results
- Chongqing Water Group Co.,Ltd. (601158.SS) Income Statement Analysis – Financial Results
- Tatton Asset Management plc (TAM.L) Income Statement Analysis – Financial Results
- S.A.I. Leisure Group Company Limited (1832.HK) Income Statement Analysis – Financial Results
- BICO Group AB (publ) (BICO.ST) Income Statement Analysis – Financial Results
Intercept Pharmaceuticals, Inc. (ICPT)
About Intercept Pharmaceuticals, Inc.
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 285.71M | 363.47M | 312.69M | 252.00M | 179.80M | 130.96M | 24.95M | 2.78M | 1.74M | 1.62M | 2.45M | 1.81M | 0.00 |
| Cost of Revenue | 984.00K | 3.10M | 5.32M | 4.21M | 2.52M | 1.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 284.73M | 360.37M | 307.37M | 247.79M | 177.29M | 129.59M | 24.95M | 2.78M | 1.74M | 1.62M | 2.45M | 1.81M | 0.00 |
| Gross Profit Ratio | 99.66% | 99.15% | 98.30% | 98.33% | 98.60% | 98.95% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 176.64M | 185.27M | 191.49M | 242.80M | 207.30M | 191.50M | 153.89M | 128.19M | 80.31M | 27.94M | 16.18M | 11.43M | 12.71M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 255.47M | 0.00 | 0.00 | 103.75M | 34.60M | 13.13M | 4.85M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -161.00 | 331.87K | 0.00 | 0.00 |
| SG&A | 176.30M | 230.86M | 332.49M | 317.42M | 255.47M | 273.70M | 273.60M | 103.75M | 34.60M | 13.13M | 5.18M | 4.21M | 3.64M |
| Other Expenses | 6.52M | 2.16M | 4.41M | 8.89M | 6.77M | 4.52M | 3.90M | 2.73M | 776.00K | 100.38K | -104.00K | 0.00 | 104.55K |
| Operating Expenses | 352.94M | 416.13M | 523.98M | 560.22M | 462.78M | 465.20M | 427.49M | 231.94M | 114.91M | 41.07M | 21.36M | 15.64M | 15.86M |
| Cost & Expenses | 353.93M | 419.23M | 529.30M | 564.43M | 465.29M | 466.57M | 427.49M | 231.94M | 114.91M | 41.07M | 21.36M | 15.64M | 15.86M |
| Interest Income | 15.51M | 47.77M | 39.80M | 33.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 61.45K | 0.00 |
| Interest Expense | 21.39M | 54.42M | 48.05M | 41.14M | 30.52M | 29.27M | 14.20M | 0.00 | 0.00 | 0.00 | 0.00 | 13.48K | 0.00 |
| Depreciation & Amortization | 6.52M | 2.16M | 4.41M | 8.89M | 4.58M | 4.60M | 3.83M | 1.69M | 442.80K | 105.68K | 201.32K | 410.60K | 479.50K |
| EBITDA | -61.70M | -53.60M | -212.20M | -303.54M | -278.72M | -331.10M | -398.63M | -226.43M | 57.66M | -10.90M | 5.71M | -14.46M | -16.06M |
| EBITDA Ratio | -21.59% | -14.75% | -67.86% | -120.45% | -155.01% | -252.83% | -1,597.67% | -8,139.07% | 3,310.10% | -672.47% | 233.52% | -801.31% | 0.00% |
| Operating Income | -68.22M | -55.76M | -216.61M | -312.43M | -285.49M | -335.61M | -402.54M | -229.16M | -113.17M | -39.45M | -18.91M | -14.88M | -16.35M |
| Operating Income Ratio | -23.88% | -15.34% | -69.27% | -123.98% | -158.78% | -256.28% | -1,613.31% | -8,237.10% | -6,496.56% | -2,432.85% | -773.25% | -824.06% | 0.00% |
| Total Other Income/Expenses | -106.64M | -35.67M | -43.64M | -32.25M | -23.75M | -24.76M | -10.29M | 2.73M | -170.06M | -28.34M | -24.73M | 0.00 | 1.27M |
| Income Before Tax | -174.86M | -91.43M | -274.88M | -344.68M | -309.24M | -360.37M | -412.83M | -226.43M | -283.23M | -67.79M | -43.64M | -13.83M | -15.09M |
| Income Before Tax Ratio | -61.20% | -25.15% | -87.91% | -136.78% | -171.99% | -275.18% | -1,654.56% | -8,139.07% | -16,258.67% | -4,180.52% | -1,784.30% | -766.17% | 0.00% |
| Income Tax Expense | -290.03M | 53.60M | 49.35M | 46.37M | 6.77M | 29.19M | 14.27M | 1.04M | 170.39M | 28.44M | 24.42M | -1.09M | -672.48K |
| Net Income | 115.17M | -145.02M | -324.23M | -391.05M | -309.24M | -360.37M | -412.83M | -226.43M | -283.23M | -67.79M | -43.64M | -12.74M | -15.09M |
| Net Income Ratio | 40.31% | -39.90% | -103.69% | -155.18% | -171.99% | -275.18% | -1,654.56% | -8,139.07% | -16,258.67% | -4,180.52% | -1,784.30% | -705.64% | 0.00% |
| EPS | 3.41 | -4.55 | -9.83 | -12.35 | -10.86 | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 | -6.95 | -3.83 | -4.53 |
| EPS Diluted | 3.40 | -4.55 | -9.83 | -12.35 | -10.86 | -14.38 | -16.74 | -9.56 | -13.63 | -3.76 | -6.95 | -3.83 | -4.53 |
| Weighted Avg Shares Out | 33.82M | 31.86M | 32.97M | 31.65M | 28.46M | 25.05M | 24.66M | 23.69M | 20.78M | 18.03M | 6.28M | 3.33M | 3.33M |
| Weighted Avg Shares Out (Dil) | 33.84M | 31.89M | 32.97M | 31.65M | 28.46M | 25.05M | 24.66M | 23.69M | 20.78M | 18.03M | 6.28M | 3.33M | 3.33M |
Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
12 of 16 voting-eligible advisors vote “no” (with two abstentions) on question, “given the available efficacy and safety data, do the benefits of OCA 25 mg outweigh the risks in NASH patients with stage 2 or 3 fibrosis?”
US FDA panel votes against accelerated approval of Intercept fatty liver drug
A panel of advisers to the U.S. Food and Drug Administration on Friday recommended holding off on an accelerated approval of Intercept Pharmaceuticals Inc's oral drug for a type of fatty liver disease until more study data is available.
Intercept Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
MORRISTOWN, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that NASDAQ has halted trading of the...
Intercept (ICPT) Down Ahead of GIDAC Meeting for NASH Treatment
Intercept (ICPT) falls 14.7% a couple of days before the scheduled GIDAC meeting to review its NASH treatment on concerns of adverse events.
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)---- $ICPT #ICPT--The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm.
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. (“Intercept” or “the Company”) (NASDAQ: ICPT) for violations of the securities laws. The investigation...
Intercept's (ICPT) Liver Drug Combo Gets FDA's Orphan Drug Tag
Intercept's (ICPT) fixed-dose combination of obeticholic acid and bezafibrate for the potential treatment of primary biliary cholangitis gets the FDA's Orphan Drug Designation.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Intercept Pharmaceuticals, Inc. (“Intercept” or “the Company”) (NASDAQ: ICPT) for violations of the securities laws. The investigation...
Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)
Company on track to complete planned interim analyses from two ongoing Phase 2 studies of the OCA-bezafibrate combination in 2023
Intercept (ICPT) Gains 26.2% YTD: What's in Store?
Intercept (ICPT) has been having a good run in the year so far, but investors are wary ahead of the upcoming advisory meeting by the FDA's Gastrointestinal Drugs Advisory Committee to review its NDA seeking approval of OCA in steatohepatitis...
Source: https://incomestatements.info
Category: Stock Reports